SCM
IMUX icon

Stonepine Capital Management’s Immunic IMUX Stock Holding History

Stonepine Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,241
Closed -$198K – 29
2021
Q3 		$198K Buy
+2,241
New +$221K 0.09% 28

Other funds holding IMUX

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Stonepine Capital Management's IMUX Position: Q4 2021 in Review

Stonepine Capital Management sold out of Immunic (IMUX) in Q4 2021, closing a stake of 2,241 shares — an estimated $198K sold.

Stonepine Capital Management first reported a position in IMUX in Q3 2021 and held it in 1 quarter. The position peaked at $198K in Q3 2021. 67 funds tracked by Wall St. Rank hold IMUX as of Q4 2021.

  • Stonepine Capital Management reported no remaining Immunic position as of Q4 2021 after selling out during the quarter.
  • Stonepine Capital Management sold 2,241 Immunic shares in Q4 2021, an estimated $198K.
  • Stonepine Capital Management first reported a position in Immunic in Q3 2021 and held it in 1 quarter.
  • Stonepine Capital Management's Immunic position peaked at $198K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Immunic as of Q4 2021.

Based on Stonepine Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.